Evaluation of the Therapeutic Efficacy of a Mindfulness-Based Stress Reduction (MBSR) Program as an Adjuvant Therapy in Patients With Moderate Pruritic Inflammatory Dermatosis (Psoriasis or Atopic Dermatitis): Skin Diseases and Conditions - Atopic Dermatitis - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Newswires
Newswires RSS Get our newsletter
Order Prints
August 31, 2022 Newswires
Share
Share
Post
Email

Evaluation of the Therapeutic Efficacy of a Mindfulness-Based Stress Reduction (MBSR) Program as an Adjuvant Therapy in Patients With Moderate Pruritic Inflammatory Dermatosis (Psoriasis or Atopic Dermatitis): Skin Diseases and Conditions – Atopic Dermatitis

Insurance Daily News

2022 AUG 31 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Staff editors report on the newly launched clinical trial, NCT05500794, which has the following summary description: “Psoriasis and atopic dermatitis are multifactorial inflammatory dermatoses, with a very high prevalence, reaching more than 120 million patients in the world. Although the physiopathological mechanisms are not yet clearly defined, these inflammatory dermatoses involve an interaction between the immune system and the epidermal cells, severe skin inflammation and often very intense pruritus. The objectives of an effective management should be to treat lesions in order to reduce them, but also to reduce itching and allow the patients to accept and cope with their pathology, without neglecting an improvement in the “Dermatology Life Quality Index” (DLQI) and in the psychological state, sometimes depressive, of the patient. Itching is defined as “a feeling that needs to be scratched urgently” and can cause significant distress along with pain. It severely impacts the quality of life and the quality of sleep. Chronic itching is associated with increased stress, anxiety, and other mood disorders. In turn, stress and anxiety exacerbate the itching, leading to a vicious cycle of pruritus - scratching that affects patient behavior (excessive scratching) and worsens disease prognosis and quality of life. Much research over the past few decades has demonstrated the effect of mindfulness meditation on emotional and cognitive responsiveness, cognitive flexibility, rumination, self-compassion and mindfulness, but also on acute pain, anxiety, stress, depression, cardiovascular disease, eating disorders, cancer and cognitive loss with age. Several studies have shown the impact of mindfulness on brain function and immunity, with evidence for the association between mindfulness and changes in the levels of markers characteristic of immune system activity and inflammation, known to be increased in psoriasis or atopic dermatitis. Our objective is to evaluate the effect of mental training in the regulation of stress and emotions through mindfulness meditation in patients with moderate, itchy atopic dermatitis or psoriasis, not treated with systemic agents (e.g.: biotherapies). This project is based on the premise that mental training in the regulation of stress and emotions through meditation would reduce the effects of the infernal itch-scratch cycle, alleviating pruritus, thus improving the well-being and mental health of patients while reducing their inflammatory skin lesions and limiting the appearance of new lesions.”

As a matter of record, on August 17, 2022, NewsRx staff editors report that the available information provided by Assistance Publique - Hopitaux de Paris on this trial include:

Tracking Information

Trial Identifier NCT05500794
First Submitted Date August 11, 2022
First Posted Date August 15, 2022
Results First Submitted Date Not Provided
Results First Posted Date Not Provided
Last Update Submitted Date August 11, 2022
Last Update Posted Date August 15, 2022
Primary Completion Date March 31, 2023
Start Date September 2022
Current Primary Outcome Measures •Pruritus assessed by Visual Analogue Scale (VAS) [ Time Frame: at 8 weeks ] -- VAS Pruritus scale is a scale going from 0 to 10. 0 corresponds to no pruritus et 10 to the maximum of prurit.
Current Secondary Outcome Measures •Pruritus assessed by Visual Analogue Scale (VAS) [ Time Frame: at 16 weeks ] -- VAS Pruritus scale is a scale going from 0 to 10. 0 corresponds to no pruritus et 10 to the maximum of prurit.
•Pruritus assessed by 5-D Itch Scale 5-D (5-D IQ) [ Time Frame: at 8 weeks ] -- The 5-D itch scale is a multidimensional questionnaire. The scores of each of the domains are achieved separately and then summed together : total 5-D score can potentially range between 5 (no pruritus) and 25 (most severe pruritus).
•Pruritus assessed by 5-D Itch Scale 5-D (5-D IQ) [ Time Frame: at 16 weeks as compared to 8 weeks ] -- The 5-D itch scale is a multidimensional questionnaire. The scores of each of the domains are achieved separately and then summed together : total 5-D score can potentially range between 5 (no pruritus) and 25 (most severe pruritus).
•Number of dermatocorticoides tubes [ Time Frame: at 8 weeks ]
•Number of dermatocorticoides tubes [ Time Frame: at 16 weeks as compared to 8 weeks ]
•Number of scratches per day (including nights) [ Time Frame: at 8 weeks ]
•Number of scratches per day (including nights) [ Time Frame: at 16 weeks as compared to 8 weeks ]
•Psorasis Area and severity index (PASI Index) for psoriasis group [ Time Frame: at 8 weeks ] -- This score takes into account the affected skin surface, the degree of redness, the thickening of the skin and the scaling. Its ranges from 0 to 72.The higher the number, the more severe the psoriasis.
•Psorasis Area and severity index (PASI Index) for psoriasis group [ Time Frame: at 16 weeks as compared to 8 weeks ] -- This score takes into account the affected skin surface, the degree of redness, the thickening of the skin and the scaling. Its ranges from 0 to 72.The higher the number, the more severe the psoriasis.
•SCORAD Index for atopic dermatitis [ Time Frame: at 8 weeks ] -- The maximal score of the SCORAD Index is 103.
•SCORAD Index for atopic dermatitis [ Time Frame: at 16 weeks as compared to 8 weeks ] -- The maximal score of the SCORAD Index is 103.
•Stress evaluation assessed by Perceived Stress Scale [ Time Frame: at 8 weeks ] -- It is a 10 questions scale with 5 items per question. Its goes from 10 to 50.
•Stress evaluation assessed by Perceived Stress Scale [ Time Frame: at 16 weeks as compared to 8 weeks ] -- It is a 10 questions scale with 5 items per question. Its goes from 10 to 50.
•Quantification of inflammatory stress markers in saliva [ Time Frame: at 8 weeks ] -- Saliva stress markers will be alpha-amylase, cortisol, IL-6, IL-31 and TNF-alpha
•Quantification of inflammatory stress markers in saliva [ Time Frame: at 16 weeks as compared to 8 weeks ] -- Saliva stress markers will be alpha-amylase, cortisol, IL-6, IL-31 and TNF-alpha
•Quantification of inflammatory stress markers in serum [ Time Frame: at 8 weeks ] -- Serum stress markers will be CRP, cortisol, IL-6, IL-3, TNF-alpha and Adreno CorticoTropic Hormone
•Quantification of inflammatory stress markers in serum [ Time Frame: at 16 weeks as compared to 8 weeks ] -- Serum stress markers will be CRP, cortisol, IL-6, IL-31,TNF-alpha and Adreno CorticoTropic Hormone
Other Outcome Measures Not Provided
Change History Complete list of historical revisions of study NCT05500794

Descriptive Information

Brief Title Meditation in Inflammatory Dermatosis
Official Title Evaluation of the Therapeutic Efficacy of a Mindfulness-Based Stress Reduction (MBSR) Program as an Adjuvant Therapy in Patients With Moderate Pruritic Inflammatory Dermatosis (Psoriasis or Atopic Dermatitis)
Brief Summary Psoriasis and atopic dermatitis are multifactorial inflammatory dermatoses, with a very high prevalence, reaching more than 120 million patients in the world. Although the physiopathological mechanisms are not yet clearly defined, these inflammatory dermatoses involve an interaction between the immune system and the epidermal cells, severe skin inflammation and often very intense pruritus. The objectives of an effective management should be to treat lesions in order to reduce them, but also to reduce itching and allow the patients to accept and cope with their pathology, without neglecting an improvement in the “Dermatology Life Quality Index” (DLQI) and in the psychological state, sometimes depressive, of the patient. Itching is defined as “a feeling that needs to be scratched urgently” and can cause significant distress along with pain. It severely impacts the quality of life and the quality of sleep. Chronic itching is associated with increased stress, anxiety, and other mood disorders. In turn, stress and anxiety exacerbate the itching, leading to a vicious cycle of pruritus - scratching that affects patient behavior (excessive scratching) and worsens disease prognosis and quality of life. Much research over the past few decades has demonstrated the effect of mindfulness meditation on emotional and cognitive responsiveness, cognitive flexibility, rumination, self-compassion and mindfulness, but also on acute pain, anxiety, stress, depression, cardiovascular disease, eating disorders, cancer and cognitive loss with age. Several studies have shown the impact of mindfulness on brain function and immunity, with evidence for the association between mindfulness and changes in the levels of markers characteristic of immune system activity and inflammation, known to be increased in psoriasis or atopic dermatitis. Our objective is to evaluate the effect of mental training in the regulation of stress and emotions through mindfulness meditation in patients with moderate, itchy atopic dermatitis or psoriasis, not treated with systemic agents (e.g.: biotherapies). This project is based on the premise that mental training in the regulation of stress and emotions through meditation would reduce the effects of the infernal itch-scratch cycle, alleviating pruritus, thus improving the well-being and mental health of patients while reducing their inflammatory skin lesions and limiting the appearance of new lesions.
Detailed Description Not Provided
Study Type Interventional
Study Phase Not Applicable
Study Design Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Other
Masking: None (Open Label)
Condition Atopic Dermatitis
Psoriasis
Pruritus
Intervention •Other: MBSR (Mindfulness-Based Stress Reduction)
MBSR (Mindfulness-Based Stress reduction) program : 1 weekly session of 2 hours and a half for 8 weeks, (first and last session: 3 hours) and an optional day of intensive practice of 6 hours, supervised by an MBSR instructor. In each weekly session, the instructor creates a supportive environment in which: Guided meditation practices; Mindfulness stretching and yoga; Reflection and group discussion periods aimed at promoting mindfulness in daily life; Practice instructions and opportunity to ask questions; Instructions for home practice. Audio recordings and a manual are provided to support personal practice. Audio recordings and a manual are provided to support personal practice
Study Arms •Experimental: MBSR (Mindfulness-Based Stress Reduction) group
MBSR (Mindfulness-Based Stress reduction) program : 1 weekly session of 2 hours and a half for 8 weeks, (first and last session: 3 hours) and an optional day of intensive practice of 6 hours, supervised by an MBSR instructor.
Interventions:
⚬Other: MBSR (Mindfulness-Based Stress Reduction)

Recruitment Information

Recruitment Status Not yet recruiting
Estimated Enrollment 72
Estimated Completion Date May 2023
Primary Completion Date March 31, 2023 (Final data collection date for primary outcome measure)
Eligibility Inclusion Criteria: Patient aged 18 years old or older With health insurance coverage Significant pruritus defined by a Visual Analogical Scale (VAS) pruritus ≥ 4 Patient with plaque psoriasis Without joint involvement Mild to moderate severity (PASI>10) DLQI > 10 OR Patient with atopic dermatitis: Mild to moderate severity (SCORAD>10) DLQI > 10 Diagnosis according to Hanifin and Raijka criteria Patient in a stable psychological state French langage spoken Exclusion Criteria : Current systemic treatment or treatment discontinued within the last month Psychiatric illnesses diagnosed according to the DSM-5 or ICD-10 international criteria of psychotic disorder, severe anxiety disorder, depressive disorder with a current depressive episode of severe intensity, bipolar disorder with a current depressive or manic episode Taking psychotropic or neuroleptic treatments Participation in another interventional research study or being in the exclusion period at the end of a previous study, if applicable Patient under AME
Sex/Gender Sexes Eligible for Study: All
Ages 18 Days and older
Accepts Healthy Volunteers No
Contacts Primary contact: Charles CASSIUS, +331.42.38.50.49, [email protected]
Backup contact: Matthieu Resche-Rigon, +33142499742, [email protected]
Listed Location Countries France
Removed Location Countries

Administrative Information

NCT Number NCT05500794
Other Study ID Numbers APHP211191
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
Plan to Share Data (IPD) Description Not Provided
Responsible Party Assistance Publique - Hopitaux de Paris
Collaborators Not Provided
Investigators Not Provided
Information Provided By Assistance Publique - Hopitaux de Paris
Verification Date August 2022

(Our reports deliver fact-based news of research and discoveries from around the world.)

Older

Patent Application Titled “Chronic Disease Prediction System Based On Multi-Task Learning Model” Published Online (USPTO 20220254493): Patent Application

Newer

Three Benefits of Universal Life Insurance

Advisor News

  • Your client wants to cash out an annuity. Here’s what to consider
  • How student loan debt impacts 401(k) balances
  • The ‘sandwich generation’ faces compounded barriers to retirement savings
  • Benefit Costs Squeeze Schools, Driving Cuts, Tax Hikes And Difficult Tradeoffs
  • Why client insurance needs could change even if their life doesn’t
More Advisor News

Annuity News

  • AM Best to Discuss Its Views on Private Credit Surge and Risks at 2026 NAIC/NIPR Insurance Summit
  • OID recovers $260M in life insurance benefits
  • NUNN BILLS TO COMBAT PAYMENT SCAMS, CUT FINANCIAL RED TAPE PASS FINANCIAL SERVICES COMMITTEE
  • SS&C Black Diamond Expands Annuities & Insurance Marketplace with New Insurance Capabilities and Carriers
  • Regulators urged to sharply limit hypothetical data in annuity illustrations
More Annuity News

Health/Employee Benefits News

  • Solutions, not slogans, are needed for rural Ohio.
  • Call for State Action as Insurance Costs Squeeze School Budgets
  • Embassy nursing home workers frustrated by repeated health coverage lapses
  • Oregon Medicaid program erroneously paid up to $4.1M due to system errors, audit says
  • Federal audit seeks $47M refund from UnitedHealthcare
Sponsor
More Health/Employee Benefits News

Life Insurance News

  • AM Best Assigns Credit Ratings to Lasso Healthcare Insurance Company
  • A-Cap insurers face new takeover push in South Carolina
  • AM Best Affirms Credit Ratings and Assigns National Scale Rating to Allianz Ayudhya General Insurance Public Company Limited
  • Winged Keel Group Welcomes Scott Henderson, Expanding Institutional Relationships and Presence Across Midwest
  • Former Wynn principal Sheckles claims age discrimination
Sponsor
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • Lauren Sinnott Named to Ragan’s Top Women in Marketing Awards, Class of 2026 
  • Classic Car Insurer OpenRoad Insurance Expands to 40 U.S. States in Two Years
  • How Aspire General Turned an Early Technology Bet Into Claims Automation at Scale with Kyber
  • Adjusto launches AI-Native contents claims services powered by its technology platform
  • URL Insurance Group Celebrates 40 Years of Service, Growth, and Industry Leadership
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.